SB 133 Summary

• Establishes the Alaska opioid settlement investment fund outside the general fund to receive appropriations from opioid manufacturer and distributor settlement agreements, with fund earnings and donations included as revenue sources.

• Directs the Commissioner of Revenue to determine annually the amount available for appropriation as five percent of the average market value of the fund over the preceding five fiscal years, with amounts appropriated to the Alaska opioid remediation fund.

• Creates the Alaska opioid remediation fund in the general fund for the Commissioner of Health to expend without further appropriation for opioid prevention, harm reduction, treatment, recovery, remediation, education, program administration, and grant awards.

• Provides a five-year transition formula for calculating appropriations from the investment fund based on initial appropriations and market values as of specific dates from June 30, 2023 through June 30, 2026.

• Takes effect June 30, 2023.